Alavez Pérez Noé Santiago, López Ibañez Juan Pablo and Velázquez Domínguez José Antonio*

Escuela Nacional de Medicina y Homeopatía, Av. Guillermo Massieu Helguera 239, La Escalera Ticomán, Gustavo A. Madero, 07320 Ciudad de México, Mexico

*Corresponding Author: Velázquez Domínguez José Antonio, Escuela Nacional de Medicina y Homeopatía, Av. Guillermo Massieu Helguera 239, La Escalera Ticomán, Gustavo A. Madero, 07320 Ciudad de México, Mexico.

Received: November 20, 2025; Published: December 20, 2025

Abstract

Objective: Analyze the participation of molecular biomarkers involved in gastrointestinal cancer (GIC).

Materials and Methods: A bibliographic selection of original and review articles reported in the last five years was conducted, which describe the role of biomarkers in the process of gastrointestinal cancer.

Results: The most frequently found biomarker in the different types of GIC is CXCR4; However, approximately 16 other biomolecules coexist and are involved in this pathology, including glycoproteins, proteoglycans, interleukins, claudins, and enzymes such as RHOA, RAC1, as well as transglutamines, fucosidases, and lactate dehydrogenases.

Conclusion: GIC is a multifactorial event resulting from the involvement of various biomarker molecules that play a significant role in progression and metastasis. Describing these mechanisms and their interactions allows for the development of potential therapeutic targets

Keywords: Biomarkers; Signaling; Gastrointestinal Cancer

References

1. Zajkowska M and Mroczko B. “The Role of Pentraxin 3 in Gastrointestinal Cancers”. Cancers 24 (2023): 1-16.
2. Wang X., et al. “LGR5 regulates gastric adenocarcinoma cell proliferation and invasion via activating Wnt signaling pathway”. Oncogenesis57 (2018): 1-14.
3. Morgan RG., et al. “Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?” British Journal of Cancer 118 (2018): 1410-1418.
4. Zhang Y and Wang X. “Targeting the Wnt/β-catenin signaling pathway in cancer”. Journal of Hematology and Oncology165 (2020): 1-16.
5. Doumpas N., et al. “TCF/LEF dependent and independent transcriptional regulation of Wnt/β‐catenin target genes”. EMBO Journal2 (2019): 1-14.
6. Abdelrahman AE., et al. “Prognostic Impact of LGR5, Prox1, and Notch1 Biomarkers in Stage II to III Colon Cancer”. Applied Immunohistochemistry & Molecular Morphology2 (2022): 126-135.
7. Kamakura M., et al. “LGR5 expression and clinicopathological features of the invasive front in the fat infiltration area of pancreatic cancer”. Diagnostic Pathology21 (2022): 1-7.
8. Bao S., et al. “CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment”. Journal of Cancer Research and Clinical Oncology 149 (2023): 7945-68.
9. Zhao H., et al. “The regulatory role of cancer stem cell marker gene CXCR4 in the growth and metastasis of gastric cancer”. npj Precis Oncology86 (2023): 1-13.
10. Romanowicz A., et al. “Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis”. International Journal of Molecular Sciences8 (2024): 1-19.
11. Chen P., et al. “The CXCR4 might be a potential biomarker for esophageal squamous cell carcinoma: A meta-analysis”. Medicine 14 (2024): 1-7.
12. Malik S., et al. “CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target”. Cancers 1 (2022): 1-17.
13. Bodoque Villar R., et al. “The importance of CXCR4 expression in tumor stroma as a potential biomarker in pancreatic cancer”. World Journal of Surgical Oncology287 (2023): 1-10.
14. Bocchi M., et al. “Involvement of CXCL12/CXCR4 axis in colorectal cancer: a mini-review”. Molecular Biology Reports 50 (2023): 6233-6239.
15. Tomuleasa C., et al. “Therapeutic advances of targeting receptor tyrosine kinases in cancer”. Signal Transduction and Targeted Therapy 201 (2024): 1-51.
16. Janjua KA., et al. “Development of Novel Cancer Biomarkers for Diagnosis and Prognosis”. In: Shehzad, A. (eds) Cancer Biomarkers in Diagnosis and Therapeutics Springer Singapore (2022): 277-243.
17. Aguirre RE and Serra MA. “Genetic and molecular biology implications for the surgical treatment of gastric cancer”. Finlay2 (2021): 18999.
18. Strickler JH., et al. “Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review”. JAMA Oncology 5 (2021): 760-769.
19. Hashimoto T., et al. “A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer”. British Journal of Cancer 129 (2023): 1176-1183.
20. Sato Y., et al. “Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives”. Journal of Clinical Medicine14 (2023): 1-22.
21. Schrumpf T., et al. “FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort”. PLOS ONE2 (2022): 1-19.
22. Huang PS., et al. “Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer”. Cells6 (2023): 1-24.
23. Hua YQ., et al. “Promoted cancer growth by stimulating cell proliferation and decreasing apoptosis using a lentivirus-based EphB2 RNAi in pancreatic carcinoma CFPAC-1 cells”. Biomed Pharmacotherapy2 (2011): 123-131.
24. Lui W., et al. “The Roles of EphB2 in Cancer”. Frontiers in Cell and Developmental Biology 10 (2022): 1-12.
25. Bai J., et al. “EphA2 promotes the transcription of KLF4 to facilitate stemness in oral squamous cell carcinoma”. Cellular and Molecular Life Sciences278 (2024): 1-16.
26. Bestari MB., et al. “A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present”. Biomolecules3 (2024): 1-16.
27. Camili C., et al. “LRG1: an emerging player in disease pathogenesis”. Journal of Biomed Science6 (2022): 1-29.
28. Cai D., et al. “LRG1 in pancreatic cancer cells promotes inflammatory factor synthesis and the angiogenesis of HUVECs by activating VEGFR signaling”. Journal of Gastrointestinal Oncology1 (2022): 400-412.
29. Basthi Mohan P., et al. “Biomarker in Hepatocellular Carcinoma”. Indian Journal of Surgical Oncology2 (2024): 261-268.
30. Zhou JM., et al. “AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis”. Medicine 43 (2021): 1-6.
31. Guo M., et al. “Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma”. Journal of Cancer 8 (2022): 2008-2021.
32. Tsung-Chieh S., et al. “Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma”. Liver Research4 (2020): 168-172.
33. Cheng E., et al. “Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer”. JAMA Oncology3 (2023): 404-413.
34. Rafique A., et al. “Toll-like receptor 13-mediated signaling protects against the development of colon cancer”. International Journal of Cancer10 (2023): 1858-1873.
35. Maryam S., et al. “Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring”. Journal of Clinical Medicine9 (2023): 1-32.
36. Chen MF., et al. “IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus”. Molecular Cancer 12 (2013): 26.
37. Abu-Khudir R., et al. “Identifying Effective Biomarkers for Accurate Pancreatic Cancer Prognosis Using Statistical”. Machine Learning Diagnostics19 (2023): 1-28.
38. Tâlvan CD., et al. “Serum Interleukins 8, 17, and 33 as Potential Biomarkers of Colon Cancer”. Cancers 4 (2024): 1-23.
39. Zhang J., et al. “Expression of interleukin-8 and integrin β3 predicts prognosis of patients with hepatocellular carcinoma after hepatectomy”. Medicine41 (2024): 1-6.
40. Mathias-Machado MC., et al. “Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?” Cancers 3 (2024): 1-18.
41. Fangqian Du., et al. “Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases”. Journal of Hepatocellular Carcinoma 11 (2024): 1801-1121.
42. Bhat AA., et al. “Claudin-1, A Double-Edged Sword in Cancer”. International Journal of Molecular Science2 (2020): 1-24.
43. Daoyu T., et al. “Expression patterns of claudins in cancer”. Heliyon 11 (2023): 1-16.
44. Crosas-Molist E., et al. “RHO GTPase Signaling in cancer progression and dissemination”. Physrev1 (2022): 455-10.
45. Nam S., et al. “RHOA in Gastric Cancer: Functional Roles and Therapeutic Potential”. Frontiers in Genetics438 (2019): 1-8.
46. Çelik C., et al. “Gelsolin and Rac1 Cytoskeleton Protein Microarray Biomarkers in Colon Cancer Metastasis”. Indian Journal of Surgery 85 (2023): 1170-1176.
47. Zhang S., et al. “Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer”. Cell Oncology 46 (2023): 1473-1492.
48. Vlasiou M., et al. “Targeting Lactate Dehydrogenase-B as a Strategy to Fight Cancer: Identification of Potential Inhibitors by in silico Analysis and in vitro Screening”. Pharmaceutics10 (2023): 1-18.
49. Xiao S and Zhou L. “Gastric cancer: Metabolic and metobolomics perspectives (Review)”. International Journal of Oncology 51 (2017): 5-17.
50. Alsina Maqueda M., et al. “Biomarcadores en cáncer gastroesofágico 2025: una declaración de consenso actualizada de la Sociedad Española de Oncología Médica (SEOM) y la Sociedad Española de Anatomía Patológica (SEAP)”. Clinical and Translational Oncology 27 (2025): 3580-3594.
51. Businello G., et al. “Evaluación actual de biomarcadores moleculares en el adenocarcinoma de la unión gástrica/gastroesofágica: el patólogo sí importa”. Updates Surgery 75 (2023): 291-303.
52. Zhang Z., et al. “Advances in molecular markers of digestive system tumors”. Minerva Medicine (2024).
53. Hajibabaie F., et al. “Identificación de un nuevo panel molecular como posibles biomarcadores para el cribado de cáncer gastrointestinal PAN: Bioinformática y análisis experimental”. Biology7 (2025): 803.
54. Zhou D., et al. “Clinical application of serum CST4 combined with tumor markers in the diagnosis of digestive system malignant tumors”. Oncology Letters2 (2024): 384.
55. Monica M., et al. “Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?” Digestive and Liver Disease12 (2020): 1503-1511.
56. Brulé SY., et al. “Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17”. European Journal of Cancer 51 (2015): 1405-1414.
57. Laura S., et al. “Tumor-Infiltrating Lymphocytes, Crohn’s-Like Lymphoid Reaction, and Survival From Colorectal Cancer”. Journal of the National Cancer Institute8 (2016): 1-8.

Citation

Citation: Velázquez Domínguez José Antonio., et al. “Biomarkers Involved in Gastrointestinal Cancer".Acta Scientific Cancer Biology 10.1 (2026): 03-16.

Copyright

Copyright: © 2026 Velázquez Domínguez José Antonio., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.